Omega Healthcare Investors (OHI) Q3 2024 earnings summary

Executive summary

• Q3 2024 FAD was $0.70/share, exceeding expectations, with net income at $115 million ($0.42/share), up from $94 million ($0.37/share) in Q3 2023.

• 2024 AFFO guidance was raised to $2.84–$2.86/share, reflecting portfolio transitions, acquisitions, and $834 million in new investments YTD.

• Over $800 million in equity issued and $900 million invested YTD, supporting a robust acquisition pipeline and deleveraging.

• Acquired the remaining 51% of the Cindat JV, adding 63 UK facilities and assuming a £188.6 million mortgage.

• 18 operators are on a cash basis for revenue recognition, representing 18.6% of revenues for the nine months ended September 30, 2024.

Financial highlights

• Q3 2024 revenues were $276 million, up from $242 million in Q3 2023, driven by acquisitions and operator transitions.

• NAREIT FFO for Q3 2024 was $196 million ($0.71/share), up from $161 million ($0.63/share) in Q3 2023.

• Adjusted FFO for Q3 2024 was $203 million ($0.74/share); FAD was $192 million ($0.70/share), both up year-over-year.

• Q3 2024 expenses were $163.3 million, down $31.2 million year-over-year, mainly due to lower impairments and credit loss recovery.

• Cash and cash equivalents at September 30, 2024, were $342.4 million, with total assets of $9.6 billion and total debt of $4.9 billion.

Outlook and guidance

• Full-year 2024 AFFO guidance increased to $2.84–$2.86/share, assuming no material changes in market interest rates or additional operators on cash-basis.

• Management expects cash sources to cover dividends, debt service, and investments for the next twelve months.

• Q4 G&A expense projected at $11.5–$13.5 million; guidance excludes further acquisitions, asset sales, and certain non-recurring items.

• Q4 assumptions include $31 million in asset sales and $119 million in new investments funded with equity.

• Industry recovery from pandemic impacts is uneven, with some operators still facing labor shortages and cost pressures.